Abstract
In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Current HIV Research
Title: Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B
Volume: 8 Issue: 3
Author(s): Katherine A. Lau, Bin Wang, Monica Miranda-Saksena, Ross Boadle, Adeeba Kamarulzaman, Kee-Peng Ng and Nitin K. Saksena
Affiliation:
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Abstract: In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Export Options
About this article
Cite this article as:
Lau Katherine A., Wang Bin, Miranda-Saksena Monica, Boadle Ross, Kamarulzaman Adeeba, Ng Kee-Peng and Saksena Nitin K., Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111151
DOI https://dx.doi.org/10.2174/157016210791111151 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Periodontal Film: A Potential Treatment Strategy for Periodontitis
Drug Delivery Letters 3D Modeling of Dengue Virus NS4B and Chikungunya Virus nsP4: Identification of a Common Drug Target and Designing a Single Antiviral Inhibitor
Current Computer-Aided Drug Design Measurement of Serum Monoamine Oxidase in Lichen Planus Patients and Its Clinical Significance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Current Cancer Drug Targets Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?
Current Protein & Peptide Science Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets The Preclinical Testing Strategy for the Development of Novel Chemical Entities for the Treatment of Asthma
Current Drug Targets Mass Spectrometry in High Throughput Screening: A Case Study on Acetyl-Coenzyme A Carboxylase using RapidFire® – Mass Spectrometry (RF-MS)
Combinatorial Chemistry & High Throughput Screening Heterocycle-thioacetic Acid Motif: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activities
Current Pharmaceutical Design Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Indication of Bevacizumab for Cerebral Radiation Necrosis
Recent Patents on Anti-Cancer Drug Discovery Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme
Current Pharmaceutical Biotechnology Requirements and Perspectives for Integrating Metabolomics with other Omics Data
Current Metabolomics Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research